These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

494 related articles for article (PubMed ID: 26651387)

  • 21. Phase II Trial of Continuous Regorafenib Dosing in Patients with Gastrointestinal Stromal Tumors After Failure of Imatinib and Sunitinib.
    Kim JJ; Ryu MH; Yoo C; Beck MY; Ma JE; Kang YK
    Oncologist; 2019 Nov; 24(11):e1212-e1218. PubMed ID: 31036770
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regorafenib for gastrointestinal malignancies : from preclinical data to clinical results of a novel multi-target inhibitor.
    Aprile G; Macerelli M; Giuliani F
    BioDrugs; 2013 Jun; 27(3):213-24. PubMed ID: 23435872
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Treatment of Regorafenib in Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib].
    Saito Y; Takahashi T; Tanaka K; Miyazaki Y; Makino T; Kurokawa Y; Yamasaki M; Nakajima K; Takiguchi S; Mori M; Doki Y
    Gan To Kagaku Ryoho; 2018 Jan; 45(1):121-123. PubMed ID: 29362328
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The management of metastatic GIST: current standard and investigational therapeutics.
    Kelly CM; Gutierrez Sainz L; Chi P
    J Hematol Oncol; 2021 Jan; 14(1):2. PubMed ID: 33402214
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimizing treatment outcomes with regorafenib: personalized dosing and other strategies to support patient care.
    Grothey A; George S; van Cutsem E; Blay JY; Sobrero A; Demetri GD
    Oncologist; 2014 Jun; 19(6):669-80. PubMed ID: 24821824
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The BRAF Status May Predict Response to Sorafenib in Gastrointestinal Stromal Tumors Resistant to Imatinib, Sunitinib, and Regorafenib: Case Series and Review of the Literature.
    Franck C; Rosania R; Franke S; Haybaeck J; Canbay A; Venerito M
    Digestion; 2019; 99(2):179-184. PubMed ID: 30179868
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gastrointestinal stromal tumor - A review of clinical studies.
    Khoshnood A
    J Oncol Pharm Pract; 2019 Sep; 25(6):1473-1485. PubMed ID: 31068088
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [A case of a gastrointestinal stromal tumor of the rectum effectively treated with continuously-administered regorafenib after failure of imatinib and sunitinib].
    Kajiura S; Hosokawa A; Nanjyo S; Nakada N; Ando T; Sugiyama T
    Nihon Shokakibyo Gakkai Zasshi; 2016 Apr; 113(4):655-61. PubMed ID: 27052395
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ESMO: regorafenib improved PFS for GIST in post-imatinib/sunitinib setting.
    Oncology (Williston Park); 2012 Nov; 26(11):1072. PubMed ID: 23330348
    [No Abstract]   [Full Text] [Related]  

  • 30. Efficacy and safety of TAS-116, an oral inhibitor of heat shock protein 90, in patients with metastatic or unresectable gastrointestinal stromal tumour refractory to imatinib, sunitinib and regorafenib: a phase II, single-arm trial.
    Doi T; Kurokawa Y; Sawaki A; Komatsu Y; Ozaka M; Takahashi T; Naito Y; Ohkubo S; Nishida T
    Eur J Cancer; 2019 Nov; 121():29-39. PubMed ID: 31536852
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An update on the safety and efficacy of regorafenib in the treatment of solid cancers.
    Chan SL; Ma BB
    Expert Opin Drug Metab Toxicol; 2014 Nov; 10(11):1607-14. PubMed ID: 25316322
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Mir O; Brodowicz T; Italiano A; Wallet J; Blay JY; Bertucci F; Chevreau C; Piperno-Neumann S; Bompas E; Salas S; Perrin C; Delcambre C; Liegl-Atzwanger B; Toulmonde M; Dumont S; Ray-Coquard I; Clisant S; Taieb S; Guillemet C; Rios M; Collard O; Bozec L; Cupissol D; Saada-Bouzid E; Lemaignan C; Eisterer W; Isambert N; Chaigneau L; Cesne AL; Penel N
    Lancet Oncol; 2016 Dec; 17(12):1732-1742. PubMed ID: 27751846
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Regorafenib: A novel tyrosine kinase inhibitor: A brief review of its therapeutic potential in the treatment of metastatic colorectal carcinoma and advanced gastrointestinal stromal tumors.
    Thangaraju P; Singh H; Chakrabarti A
    Indian J Cancer; 2015; 52(3):257-60. PubMed ID: 26905101
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mixed response on regorafenib treatment for GIST (gastro-intestinal stromal tumor) according to
    Van Weehaeghe D; Gheysens O; Vandecaveye V; Schöffski P; Van Laere K; Deroose CM
    BMC Cancer; 2018 Mar; 18(1):253. PubMed ID: 29506493
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Single dose regorafenib-induced hypertensive crisis.
    Yilmaz B; Kemal Y; Teker F; Kut E; Demirag G; Yucel I
    Exp Oncol; 2014 Jun; 36(2):134-5. PubMed ID: 24980770
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regorafenib as a single-agent in the treatment of patients with gastrointestinal tumors: an overview for pharmacists.
    Rey JB; Launay-Vacher V; Tournigand C
    Target Oncol; 2015 Jun; 10(2):199-213. PubMed ID: 25213039
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor after treatment with imatinib: a plain language summary of the phase 3 INTRIGUE trial.
    Symcox M; Jones RL
    Future Oncol; 2023 Nov; 19(36):2383-2393. PubMed ID: 37594164
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emerging drugs for the treatment of gastrointestinal stromal tumors.
    Pilco-Janeta DF; García-Valverde A; Gomez-Peregrina D; Serrano C
    Expert Opin Emerg Drugs; 2021 Mar; 26(1):53-62. PubMed ID: 33645383
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An Unusual Case of Central Retinal Vein Occlusion and Review of the Toxicity Profile of Regorafenib in GIST Patients.
    Schvartsman G; Wagner MJ; Zobniw CM; Trinh VA; Patel S; Somaiah N
    Curr Oncol Rep; 2016 Aug; 18(8):49. PubMed ID: 27319943
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis.
    Montemurro M; Gelderblom H; Bitz U; Schütte J; Blay JY; Joensuu H; Trent J; Bauer S; Rutkowski P; Duffaud F; Pink D
    Eur J Cancer; 2013 Mar; 49(5):1027-31. PubMed ID: 23140824
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.